Medicure announces filing of ANDA in collaboration with Apicore
Wednesday, December 14, 2016
Medicure Inc., a leading Canadian specialty pharmaceutical company, is pleased to announce that an abbreviated New Drug Application ("ANDA") was filed with the U.S. Food and Drug Administration for a high-value cardiovascular generic drug developed as a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore"). The ANDA filing is the result of a project that was previously announced on January 6, 2016 and was focused on the development of an intravenous drug product for an acute cardiovascular indication. Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.
Medicure owns a majority interest in Apicore, as well as an option to acquire the remaining issued shares of Apicore until July 2017.
